From: Risk factors of fracture following curettage for bone giant cell tumors of the extremities
Variable (n = 284) | No. of patients | Filler | ||
---|---|---|---|---|
Sex |  | PMMA bone cement alone (n = 124) | PMMA bone cement and allograft bone grafting (n = 81) | Allograft or hydroxyapatite grafting (n = 79) |
Male | 131 (46.1%) | 58 (46.4%) | 43 (53.1%) | 30 (38.5%) |
Female | 153 (53.9%) | 67 (53.6%) | 38 (46.9%) | 48 (61.5%) |
Age (years) | ||||
 Median | 30 | 30.7 | 28.4 | 29.5 |
 Interquartile range | 23.2–40.3 | 26.0–42.2 | 21.9–38.3 | 21.5–40.8 |
Site | ||||
 Distal radius | 21 (7.4%) | 12 (9.7%) | 1 (1.2%) | 8 (10.1%) |
 Proximal femur | 13 (4.6%) | 1 (0.8%) | 5 (6.2%) | 7 (8.9%) |
 Distal femur | 94 (33.1%) | 56 (45.1%) | 28 (34.6%) | 10 (12.7%) |
 Proximal tibia | 95 (33.5%) | 35 (28.2%) | 37 (45.7%) | 23 (29.1%) |
 Distal tibia | 16 (5.6%) | 5 (4.0%) | 4 (4.9%) | 7 (8.9%) |
 Proximal humerus | 12 (4.2%) | 8 (6.5%) | 1 (1.2%) | 3 (3.8%) |
 Othersa | 33 (11.6%) | 8 (6.5%) | 5 (6.2%) | 20 (25.3%) |
Campanacci classification | ||||
 Stage I | 7 (2.5%) | 1 (0.8%) | 2 (2.5%) | 4 (5.1%) |
 Stage II | 220 (77.5%) | 101 (80.8%) | 60 (74.1%) | 59 (75.6%) |
 Stage III | 57 (20.1%) | 23 (18.4%) | 19 (23.5%) | 15 (19.2%) |
Pathological fracture at presentation | ||||
 No | 267 (94.0%) | 118 (94.4%) | 80 (98.8%) | 69 (88.5%) |
 Yes | 17 (6.0%) | 7 (5.6%) | 1 (1.2%) | 9 (11.5%) |
Denosumab administration | ||||
 No | 254 (89.4%) | 107 (85.6%) | 76 (93.8%) | 71 (91.0%) |
 Yes | 30 (10.6%) | 18 (14.4%) | 5 (6.2%) | 7 (9.0%) |
Previous surgery | ||||
 No | 251 (88.4%) | 109 (87.2%) | 72 (88.9%) | 70 (89.7%) |
 Yes | 33 (11.6%) | 16 (12.8%) | 9 (11.1%) | 8 (10.3%) |
Local adjuvant therapy | ||||
 No | 37 (13.0%) | 19 (15.2%) | 2 (2.5%) | 16 (20.5%) |
 Yes | 247 (87.0%) | 106 (84.8%) | 79 (97.5%) | 62 (79.5%) |
Fracture | ||||
 No | 274 (96.5%) | 116 (92.8%) | 80 (98.8%) | 78 (100%) |
 Yes | 10 (3.5%) | 9 (7.2%) | 1 (1.2%) | 0 |
Local recurrence | ||||
 None | 217 (76.4%) | 102 (81.6%) | 65 (80.3%) | 51 (65.4%) |
  ≥ 1 | 67 (23.6%) | 23 (18.4%) | 16 (19.8%) | 27 (34.6%) |
Follow-up (months) | ||||
 Median | 86.5 | 83.2 | 94.5 | 88.3 |
 Interquartile range | 50.3–118.8 | 45.8–101.9 | 63.6–133.0 | 45.3–144 |